TIL Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Instil Bio

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Instil Bio

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

2 months ago - By: Instil Bio

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

3 months ago - By: The Motley Fool

Instil Bio Posts Wider Loss in Q2

3 months ago - By: Instil Bio

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

5 months ago - By: Zacks Investment Research

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

3 months ago - By: Instil Bio

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Instil Bio

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

4 months ago - By: Instil Bio

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

5 months ago - By: Benzinga - Mentions: CNC GNTA SBFM SNGX ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

5 months ago - By: Instil Bio

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

5 months ago - By: Instil Bio

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

5 months ago - By: Yahoo Finance - Mentions: VZ AMZN WMT EPD ...

Mark Cuban Wants You To Stop Saving Money (And Do This Instead)

5 months ago - By: Instil Bio - Mentions: ALNY

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

5 months ago - By: Instil Bio

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

6 months ago - By: Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

6 months ago - By: Benzinga - Mentions: TLPH FGEN MLTX ANL ...

12 Health Care Stocks Moving In Monday's After-Market Session

6 months ago - By: Zacks Investment Research - Mentions: MRK SMMT BNTX

Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results

6 months ago - By: Instil Bio

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

6 months ago - By: Instil Bio

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

6 months ago - By: Instil Bio

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

6 months ago - By: Instil Bio

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

6 months ago - By: Zacks Investment Research

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?

6 months ago - By: Zacks Investment Research

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade

6 months ago - By: Instil Bio

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

6 months ago - By: Instil Bio

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

6 months ago - By: Instil Bio

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated

6 months ago - By: Instil Bio

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated

INSTIL BIO INC (TIL) Stock News

TIL Latest News, Press Relases and Analysis